origene technologies capabilities overview feb 2011

16
Developing Better Assays for Every Human Protein OriGene Technologies, Inc. Mark E. Watson Sr. Director Business Development Phone: (240)994-6873 Email: [email protected]

Upload: mwatson26

Post on 14-Jun-2015

1.695 views

Category:

Documents


0 download

DESCRIPTION

Opportunity overview with OriGene Technologies. OriGene is looking to identify strategic collaboration partners for its full-length human proteins, validated monoclonal antibodies and "gene centric" tool box.

TRANSCRIPT

Page 1: OriGene Technologies Capabilities Overview Feb 2011

Developing Better Assays for Every Human Protein

OriGene Technologies, Inc.

Mark E. WatsonSr. Director Business Development

Phone: (240)994-6873Email: [email protected]

Page 2: OriGene Technologies Capabilities Overview Feb 2011

Collaboration Opportunities with OriGene

• Strategic Licensing Agreements

• Supply agreement for cDNA clones, full-length human proteins and validated monoclonal antibodies

-Purchase of full cDNA clone collection or subsets-Human and Mouse ORF clones available -Bulk full-length protein development -Licensing of hybridoma cell lines (e.g. TrueMAB mAbs)-Joint mAb and/or Hybridoma cell line development -Custom multiplex assay development

• Collaboration agreements for antibody decoding and auto-antibody studies using the proprietary protein lysate microarray technology from OriGene

• Custom service projects leveraging gene synthesis capabilities from Blue Heron Biotechnology, including codon & antibody optimization

Page 3: OriGene Technologies Capabilities Overview Feb 2011

OriGene’s Key Capabilities• Largest collection of cDNA clones in the world • Protein production in human cells

– 12,000 transfected antigen lysates– 5,000 purified proteins from HEK293Tcells– Est.10,000 available by the end of 2011– Heavy-labeled MRM/Mass spec. standards.

• High throughput mAb production/ validation – Recently opened second facility to expand production to over 500 released and fully

validated mAbs/month– Three fold increase in production capabilities by year end 2011

• Cytomyx tissue bank: – >140,000 tissue samples – High throughput IHC validation capabilities

• Synthetic Gene Production & Services– Blue Heron Biotechnology Acquisition (Ab & Codon optimization)

• 10,000 Antigen Chip (Autoimmune & Cancer tests)• Luminex multiplex assay development (Marligen acquisition)

Page 4: OriGene Technologies Capabilities Overview Feb 2011

Complete Gene/clone Resource

Clones/genes Proteins Antibodies Assays

TrueORF/GoldHuman/mouseExpression vectors

True Proteins5,000 humanCustom purification

TrueMAB>1,800 mAbsIHC, IF, IP, FC, WB

TruePlex

Any speciesAny sequencesAny variants

Optimized expression

Antibody engineering Multiplex Assays

Page 5: OriGene Technologies Capabilities Overview Feb 2011

High Throughput Work Flow

15,000TrueORF Clones

12,000Over-expression Lysates

5,000Purified Protein

Transient Transfection(MegaTran)

Cell Lysates AffinityColumn

Largest offering of mammalian cell expressed human proteins

Page 6: OriGene Technologies Capabilities Overview Feb 2011

Highest Quality Standard

Not just sequence-verification

But also,

Expression Validation on 12,000 TrueORF clones

APO3C

TrueORF:RC206566

ORF size: 300 bp

Predicted MW: 11 kd

TP53

TrueORF:RC200003

ORF size: 1182 bp

Predicted MW: 53 kd

ENC1

TrueORF:RC201842

ORF size: 1770 bp

Predicted MW: 65 kd

LRP1

TrueORF:RC218369

ORF size: 13635 bp

Predicted MW: 504 kd

CDH3

TrueORF:RC207346

ORF size: 2490 bp

Predicted MW: 91 kd

Page 7: OriGene Technologies Capabilities Overview Feb 2011

Transfected Over-Expression Lysates

• 12,000 TrueORF clone transfected HEK293T cell lysates

• Mammalian cell expressed full length, WB validated

• Delivered in modified RIPA buffer to preserve protein function

• Ideal tools for antibody validation, protein function studies, and as assay standards

Page 8: OriGene Technologies Capabilities Overview Feb 2011

Over-expression Lysates

• OriGene over-expression lysates adopted in Antibody Atlas Program to validate polyclonal antibodies (e.g. Atlas Antibodies).

• Improved validation success rate from 32% with regular cell lysates to 89% with over-expression lysates.

• Data from Prof Mathias Uhlén, Program Director.

Page 9: OriGene Technologies Capabilities Overview Feb 2011

Using OriGene antigen microarray chip technology to decode antibodies that were generated by whole cell immunization

Anti-DDK (Rabbit) Anti-E-Cadherin1 (mAb)

Enlarged image

E-Cadherin1

10,000 Lysate Protein Arrays

Page 10: OriGene Technologies Capabilities Overview Feb 2011

Full Length Human Proteins

• Produced from TrueORF cDNA clones

• 5,000 full length human proteins

• Expressed in HEK293 cells

• Optimal preservation of protein structure, post-translational modifications and functions

Page 11: OriGene Technologies Capabilities Overview Feb 2011

Human Protein Activity

mTOR Activity Assay

Homogeneous time-resolved fluorescent (HTRF®) assay.

mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. mTOR belongs to the phosphatidylinositol 3-kinase-related kinase protein family.

First commercial provider of active, full-length human mTOR protein

Page 12: OriGene Technologies Capabilities Overview Feb 2011

MS Collaboration with ISB

• Generate signature peptide sequences for all 5,000 human proteins – Sequences will be in PeptideAtlas database

• Heavy-isotope labeled purified proteins– 5,000 available now for SRM/MRM application

• Isotope labeled peptides –Coming in 2011 for all 5,000 human protein

Page 13: OriGene Technologies Capabilities Overview Feb 2011

mAbs for Every Human Protein

Dedicated mAb production center - Capacity: +200 immunizations per month

Authentic proteins as antigens- Full length proteins made in human cells

Extensive validation- WB: 9 different cell lines- IHC: 24 different tissues - IF- Flow cytometry- Luminex- Additional validation available

Hybridoma cell lines for licensing- High value targets available: ERCC1, LGR5,

HES1 & NOTCH1

Goal: To produce high quality mAbs to every human proteins in 5-10years

Page 14: OriGene Technologies Capabilities Overview Feb 2011

HTP Validation of mAbs

IHC data for human carcinoma liver tissue

Anti-KRT WB with OriGene over expression lysate

Anti-KRT WB with cell panel of 9 different cell lines(For endogenous protein detection in cell line)

ERCC1 (4F9)ERCC1 (1A3)IF data with A549 cells IF data with A549 cells

Page 15: OriGene Technologies Capabilities Overview Feb 2011

0

5000

10000

15000

20000

25000

30000

1 10 100 1000 10000

Analyte Concentration (pg/ml)

FGF -4

VEGF -D

EGF

HGF

PlGF

VEGF -A

Med

ian

Fluo

resc

ent I

nten

sity

Quantitation of 6 Growth Factors in an 11-plex ELISA

Immunoassay Development

Page 16: OriGene Technologies Capabilities Overview Feb 2011

Summary

OriGene has developed the most comprehensive genome wide product solutions available

Leading developer of high quality reagents and multiplex assays for every human protein

OriGene is your perfect partner for companion diagnostic and biomarker assay development

Additional information available at:

www.origene.com